Enzomenib

Enzomenib
Clinical data
Other names	DSP-5336
Identifiers
	IUPAC name 5-fluoro-2-[4-[7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide;
CAS Number	2412555-70-3;
PubChem CID	146430058;
DrugBank	DB18514;
ChemSpider	129534736;
UNII	VW83Y2JLZ5;
ChEMBL	ChEMBL5314915;
Chemical and physical data
Formula	C33H43FN6O3
Molar mass	590.744 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C(=O)[C@@H]5[C@@H]6CC[C@H](N5)CC6=C;
	InChI InChI=InChI=1S/C33H43FN6O3/c1-20(2)40(21(3)4)31(41)26-15-23(34)6-9-27(26)43-28-16-35-19-36-30(28)39-17-33(18-39)10-12-38(13-11-33)32(42)29-25-8-7-24(37-29)14-22(25)5/h6,9,15-16,19-21,24-25,29,37H,5,7-8,10-14,17-18H2,1-4H3/t24-,25+,29-/m0/s1; Key:JQHJEDMMWUIYCE-FVVBACEJSA-N;

Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia.^[1] It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins.^[2] Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.^[3]

The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.^[4]

References

^ "Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG.
^ Dempke WC, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (September 2023). "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology. 149 (11): 9451–9459. doi:10.1007/s00432-023-04752-9. PMID 37103568.
^ "Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd. 14 June 2024.
^ Flaherty C (15 July 2024). "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG.

[pmid37103568-2] Dempke WC, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (September 2023). "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology. 149 (11): 9451–9459. doi:10.1007/s00432-023-04752-9. PMID 37103568.

[3] "Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd. 14 June 2024.

[4] Flaherty C (15 July 2024). "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive.

[1]

[2]

[3]

[4]